Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder.

Plain-language guide to PMID 41474196 (2026): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin.

Key Facts

PMID: 41474196
Journal: The international journal of neuropsychopharmacology
Year: 2026
Study type: Randomized Controlled Trial
Authors: Tyler RE et al. (12 authors)
DOI: 10.1093/ijnp/pyaf081
Registered trial: NCT02707055

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin, published as a randomized controlled trial.

Ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2) act via the growth hormone secretagogue receptor (GHSR), which modulates feeding, alcohol use, and endocrine and immune system function.

This study aimed to characterize the effects of PF-5190457 on endocrine and immune markers in individuals with AUD.

Why It Was Studied

ClinicalTrials.gov Identifier: NCT02707055; registered November 3, 2016.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

Pre-planned analyses used data from a randomized, double-blind, placebo-controlled, crossover human laboratory study in recently abstinent inpatients with AUD (N = 29; 8 females).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Additional exploratory analyses examined relationships between PK, PD, and behavioral measures.

What Was Measured

Topics PubMed links to this paper include Alcoholism, Receptors, Ghrelin, Alcohol Abstinence, Ghrelin, Azetidines, Blood Proteins and Spiro Compounds.

Author keywords: GHSR, LEAP2, PF-6870961 and growth hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The international journal of neuropsychopharmacology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Ghrelin compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.